Translational algorithms are truly essential parts of either preclinical or clinical trial protocols once new innovative drug is the case. This point, however, is no doubt treating differently in countries with different social/cultural traditions and, besides, with different medicine-related juridical backgrounds. Thus, some anti-tumor applicable medicinal nanoparticles are in a focus of the long-term preclinical research programs adopted for 2020-2025 period by Shanghai Cooperation Organization (SCO) [1,2]. Noteworthy, this regional political-economic association of nine Asian countries (China, Russia, Iran, India, Pakistan, Kazakhstan, Uzbekistan, Tajikistan, Kyrgyzstan: infoshos.ru/ en/?id=6, infoshos.ru/en/?id=51) with a total annual budget of nearly USD 26.8 bln is now takes care of support for current developments in novel pharmacophore tests aiming to optimize preclinical studies by increase of role and significance of the In Silico nanopharmacology models [2,3].